Dr Diamantis MD MRCP PhD is a consultant medical oncologist and clinical lead for colorectal cancer. His research interests include immunotherapy for gastro-intestinal malignancies and first-in-human clinical trials.

He is principal investigator for a number of phase 2/3 clinical trials.




• Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
N Engl J Med 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
• Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
JAMA Netw Open. 2022 Feb 1;5(2):e220130. doi: 10.1001/jamanetworkopen.2022.0130.
• Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry
JAMA Oncol 2022 Jan 1;8(1):114-122. doi: 10.1001/jamaoncol.2021.6199.
• Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
Lancet Oncol 2021 Dec;22(12):1669-1680. doi: 10.1016/S1470-2045(21)00573-8.
• Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Br J Cancer 2020 Oct;123(9):1360-1369. doi: 10.1038/s41416-020-1010-8.
• The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials
Eur J Cancer 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31

Research interests include immunotherapy for GI malignancies, neuroendocrine tumours and first in human clinical trials.